Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Bladder Cancer

9 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCURO1322

    03/28/2014

    Vanderbilt Assessment of Shed ALCAM in Urogenital Cancers (VanSA)

    Treatment

    VICCURO15119

    06/14/2016

    Phase II Trial of Palbociclib (PD-0332991) in Patients with Metastatic Urothelial Cancer (UC) after Failure of First-Line Chemotherapy

    Treatment

    VICCGI15126

    05/03/2016

    A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

    Treatment

    NRGUROGU001

    02/29/2016

    Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer

    Treatment

    ECOGUROS1314

    01/18/2016

    A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCHEMP1558

    10/09/2015

    A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

    Treatment

    ECOGUROEA8141

    08/27/2015

    A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

    Treatment

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor